Activation Capital

Activation Capital, founded in 2017 and based in Richmond, Virginia, serves as a key player in the knowledge-based innovation and entrepreneurial community. The firm focuses on strengthening the regional innovation ecosystem by investing in organizations that address specific gaps and strategies identified by the Activation Council. It offers a range of support to its clients, including mentorship, networking opportunities, workspace, events, talent acquisition, and funding. Activation Capital primarily invests in companies within the advanced pharmaceuticals and manufacturing sectors, emphasizing a commitment to leadership, risk management, and collaborative success.

Kipton Currier

VP of Operations

Beth O'Donnell

VP of Finance

Jim Pannucci

VP of Entrepreneurship

11 past transactions

Light Switch Bio

Non Equity Assistance in 2024
Light Switch Bio specializes in pre-clinical services for pharmaceutical companies, focusing on mitigating systemic toxicities of drugs. They repurpose existing drugs, using a proprietary laser-targeted drug delivery system to activate medications precisely where needed in the body, reducing adverse effects. This precision enhances patient outcomes and expands market reach for their clients. Additionally, they co-develop software to de-risk R&D, optimize clinical dosimetry, and improve response predictability.

Peel Therapeutics

Non Equity Assistance in 2024
Peel Therapeutics, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, focused on developing innovative cancer therapies utilizing proteins derived from elephants. Established in 2015, the company has harnessed the unique properties of elephant p53 (EP53) nanoparticles to create treatments aimed at enhancing patient outcomes in oncology. Peel Therapeutics aims to regulate cellular responses to environmental stresses by stimulating gene transcription associated with cell cycle arrest, apoptosis, and metabolism. In addition to its core focus on cancer treatment, the company is actively exploring new therapeutic avenues for both cancer and inflammatory diseases, leveraging the evolutionary advantages found in nature to address complex health challenges.

KeViRx

Non Equity Assistance in 2024
KeViRx is a biotechnology company focused on developing innovative therapeutics for cancer and respiratory disorders. The company specializes in drug discovery and is advancing new small molecule therapeutics towards clinical testing. KeViRx is currently working on an allosteric protein tyrosine phosphatase small molecule inhibitor that has shown efficacy in preclinical models for conditions such as ovarian cancer, acute myeloid leukemia, and acute lung injury. By concentrating on these areas, KeViRx aims to address significant unmet medical needs in oncology and respiratory health.

Vizma Life Sciences

Non Equity Assistance in 2024
Vizma Life Sciences develops next-generation molecular imaging and chemical analysis solutions.

Rapid Forensic Cell Typing

Non Equity Assistance in 2024
Rapid Forensic Cell Typing (RFC) is a company that specializes in advanced DNA testing services for forensic investigators. Their innovative process, using imaging flow cytometry, determines the origin, age, and type of cells in evidence samples, helping labs prioritize samples for optimal profiling results. This adds a critical layer of analysis to DNA evidence, aiding in more efficient and accurate investigations.

GenAssist

Non Equity Assistance in 2024
GenAssist began commercializing biomimetic sponges to treat muscle loss in human patients after observing a notable recovery in muscular function after a composite trauma model of muscle loss.

Oncoustics

Non Equity Assistance in 2024
Oncoustics develops AI-enhanced ultrasound technology to analyze raw ultrasound signals from handheld devices, enabling rapid differentiation between healthy and diseased tissue. The approach generates novel acoustic biomarkers and supports non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical needs. The company aims to improve clinical workflow productivity and has pursued regulatory pathways such as FDA Breakthrough Device designation for its OnX liver fibrosis detection, with 510(k) submission in progress, and plans for follow-on liver and other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

Gisens Biotech

Non Equity Assistance in 2024
Gisens Biotech is a biotechnology company focused on bioelectronics and nanotechnology, developing portable diagnostics such as the Nano-Lab, a device that provides real-time measurements of biomarkers from tiny samples of blood, urine, or saliva. The Nano-Lab aims to deliver accurate, portable biomarker analysis and interpretation, potentially changing how measurements are performed. The company is also pursuing a nanotechnology-based platform to diagnose and monitor renal biomarkers—urea, creatinine, and potassium—from a single blood drop, with results accessible through an application for real-time health monitoring.

OrthoPreserve

Non Equity Assistance in 2024
OrthoPreserve is a medical technology company specializing in the development and distribution of artificial meniscus replacement implants. These implants are designed to mimic the function of the natural meniscus, a crucial shock absorber in the knee, and are intended to treat meniscus injuries. By replacing the damaged meniscus, OrthoPreserve's implants aim to alleviate pain, restore mobility, and prevent the progression of arthritis, thereby improving patients' quality of life and long-term knee health.

Atticus Pharma

Non Equity Assistance in 2024
Atticus Pharma specializes in innovative drug delivery systems, focusing on improving the bioavailability and effectiveness of topically applied therapeutics for immunodermatological conditions and wound healing. Their unique, sustained-release technology enables direct delivery of drugs to the skin, representing a significant advancement in the field.

Lighthouse Labs RVA

Grant in 2017
Lighthouse Labs RVA helps entrepreneurs grow their startups by providing resources and support to validate business models and attract customers. Their accelerator lab program has successfully worked with 33 companies in the past 5 years, helping them raise over $25 million in financing. With a focus on real customer validation and a strong team of founders, Lighthouse Labs RVA assists startups in reaching their full potential. Whether you are looking to raise capital, bootstrap your idea, or crowdfund your business, they offer pre-acceleration resources to help you prepare for success.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.